Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning.

The ability to engraft significant numbers of genetically modified hematopoietic stem and progenitor cells without the requirement for fully myeloablative conditioning therapy is a highly desirable goal for the treatment of many nonmalignant hematologic disorders. The aims of this study were to examine, in nonhuman primates (rhesus), (1) the effects of pretreatment of host animals with cytokines (G-CSF and SCF), i.e., before nonmyeloablative irradiation, on the degree and duration of neo gene marking of circulating leukocytes after autologous cell reinfusion and (2) to compare transduction of primitive hematopoietic target cells in the presence of our standard transduction cytokine combination of IL-3, IL-6, and stem cell factor (SCF) and in the presence of an alternative combination containing SCF, G-CSF, and the thrombopoietin analog MGDF. Cytokine-mobilized rhesus peripheral blood progenitor/stem cells (PBSCs) were enriched for CD34+ cells and transduced with neo vectors (either G1Na or LNL6) for 96 hr in cultures containing rhIL-3, rhIL-6, and rhSCF or MGDF, rhSCF, and rhG-CSF and cryopreserved. Four animals underwent minimal myeloablative conditioning with 500 cGy irradiation with or without pretreatment with SCF and G-CSF, followed by reinfusion of the cryopreserved cells on the subsequent day. Neutrophil nadirs (< or =500/mm3) were 0-3 days in duration; there were no significant periods of severe thrombocytopenia. Marking of circulating granulocytes and mononuclear cells was extensive and durable in all animals (exceeding 12% in the mononuclear cells of one animal) and persisted beyond the final sampling time in all animals (up to 33 weeks). No difference in extent or duration of marking was attributable to either cytokine presensitization of recipients prior to irradiation, or to the substitution of MDGF and G-CSF for IL-3 and IL-6 during transduction.

[1]  M. Dinauer,et al.  Gene therapy for chronic granulomatous disease , 2004 .

[2]  S. Gerson.  Drug resistance gene transfer: Stem cell protection and therapeutic efficacy. , 2000, Experimental hematology.

[3]  R. Hoffman,et al.  Role of mesenchymal stem cells in hematopoietic stem cell transplantation , 2000, Current opinion in hematology.

[4]  M. Sadelain,et al.  Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells , 2000, Current opinion in hematology.

[5]  Y. Sakiyama,et al.  Adenosine deaminase deficiency as the first target disorder in gene therapy , 2000, Expert opinion on investigational drugs.

[6]  R. Mulligan,et al.  One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined immune-deficient repopulating cells using high-titer vesicular stomatitis virus G protein pseudotyped retrovirus. , 1999, Blood.

[7]  R. Schiffmann,et al.  Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. , 1998, Human gene therapy.

[8]  D. Clapp,et al.  Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in non-obese diabetic/severe combined immune-deficient mice. , 1998, Blood.

[9]  J. Rasko,et al.  Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. , 1998, Blood.

[10]  J. Tisdale,et al.  Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. , 1998, Blood.

[11]  F. Hirayama,et al.  Negative regulation by interleukin-3 (IL-3) of mouse early B-cell progenitors and stem cells in culture: transduction of the negative signals by betac and betaIL-3 proteins of IL-3 receptor and absence of negative regulation by granulocyte-macrophage colony-stimulating factor. , 1998, Blood.

[12]  K. Weinberg,et al.  T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates , 1998, Nature Medicine.

[13]  P. Quesenberry,et al.  Repetitive bone marrow transplantation in nonmyeloablated recipients. , 1998, Experimental hematology.

[14]  J. Nolta,et al.  Engraftment and retroviral marking of CD34+ and CD34+CD38- human hematopoietic progenitors assessed in immune-deficient mice. , 1998, Blood.

[15]  David A. Williams,et al.  Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells. , 1997, Human gene therapy.

[16]  S. Holland,et al.  Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Malech,et al.  Prospects for gene therapy of neutrophil defects. , 1997, Seminars in hematology.

[18]  T. Shimada,et al.  Evaluation of a Cytokine Combination Including Thrombopoietin for Improved Transduction of a Retroviral Gene into G‐CSF‐Mobilized CD34+ Human Blood Cells , 1997, Stem cells.

[19]  J. Dick,et al.  Quantitative Analysis Reveals Expansion of Human Hematopoietic Repopulating Cells After Short-term Ex Vivo Culture , 1997, The Journal of experimental medicine.

[20]  K. Cowan,et al.  Retroviral gene transduction of adult peripheral blood or marrow-derived CD34+ cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo. , 1997, Blood.

[21]  S. Holland,et al.  Enhanced host defense after gene transfer in the murine p47phox-deficient model of chronic granulomatous disease. , 1997, Blood.

[22]  H. Ramshaw,et al.  Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment. , 1997, Experimental hematology.

[23]  C. Hannum,et al.  FLT3 ligand preserves the ability of human CD34+ progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated transduction. , 1997, Blood.

[24]  D. Bodine,et al.  Improved retroviral gene transfer into murine and Rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  V. V. van Beusechem,et al.  Gene transfer into hematopoietic stem cells of nonhuman primates. , 1996, Human gene therapy.

[26]  D. Bodine,et al.  Bone marrow collected 14 days after in vivo administration of granulocyte colony-stimulating factor and stem cell factor to mice has 10-fold more repopulating ability than untreated bone marrow , 1996 .

[27]  H. Malech,et al.  Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. , 1996, Blood.

[28]  F. Hirayama,et al.  Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Emerson,et al.  Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: the next generation of cellular therapeutics. , 1996, Blood.

[30]  R. Donahue,et al.  Peripheral blood CD34+ cells differ from bone marrow CD34+ cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with granulocyte colony-stimulating factor and/or stem cell factor. , 1996, Blood.

[31]  C. Dunbar,et al.  Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. , 1996, Annual review of medicine.

[32]  N. Young,et al.  Gene marking and gene therapy directed at primary hematopoietic cells , 1996, Current opinion in hematology.

[33]  K. Weinberg,et al.  Engraftment of gene–modified umbilical cord blood cells in neonates with adenosine deaminase deficiency , 1995, Nature Medicine.

[34]  R. Schiffmann,et al.  Transfer of the human glucocerebrosidase gene into hematopoietic stem cells of nonablated recipients: successful engraftment and long-term expression of the transgene. , 1995, Blood.

[35]  A. Nienhuis,et al.  Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. , 1995, Blood.

[36]  P. Quesenberry,et al.  Murine marrow cells expanded in culture with IL-3, IL-6, IL-11, and SCF acquire an engraftment defect in normal hosts. , 1995, Experimental hematology.

[37]  F. Appelbaum,et al.  Rapid engraftment by peripheral blood progenitor cells mobilized by recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in nonhuman primates , 1995 .

[38]  A. Farese,et al.  Therapeutic efficacy of recombinant interleukin-6 (IL-6) alone and combined with recombinant human IL-3 in a nonhuman primate model of high-dose, sublethal radiation-induced marrow aplasia. , 1994, Blood.

[39]  F. Hirayama,et al.  Negative regulation of early B lymphopoiesis by interleukin 3 and interleukin 1 alpha. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Donald W. Pfaff,et al.  Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain , 1994, Nature Genetics.

[41]  J. Ihle,et al.  Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients , 1993, The Lancet.

[42]  P. Quesenberry,et al.  Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. , 1993, Blood.

[43]  C. Dunbar,et al.  Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells. , 1993, Experimental hematology.

[44]  A. Keating,et al.  Hematopoietic stem cells engraft in untreated transplant recipients. , 1993, Experimental hematology.

[45]  S. Kamel‐Reid,et al.  Autologous transplantation of canine long-term marrow culture cells genetically marked by retroviral vectors. , 1992, Blood.

[46]  A. Miller,et al.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production , 1986, Molecular and cellular biology.